HALOHalozyme Therapeutics, Inc.
Is it growing?
Neither accelerating nor breaking down: revenue growing +41% year on year, but earnings down −22% year on year and operating margin narrowing (−20.3 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +32% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 37.4% now against 57.7% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is HALO growing?
Halozyme Therapeutics, Inc. has grown revenue 29% a year over three years and 32% a year over five, with earnings per share compounding at 26%.
Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +32%
Revenue growth, 5-year rate · +29% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- +26%
Earnings per share, 3-year rate · revenue +29% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 17
Years of annual history on file · FY2009 to FY2025, as filed
Details›
- Revenue FY2021
- $443M
- Revenue FY2022
- $660M
- Revenue FY2023
- $829M
- Revenue FY2024
- $1.02B
- Revenue FY2025
- $1.40B
Annual income statements as filed with the SEC.